Increasing Use of Extracorporeal Life Support Systems
Extracorporeal life support (ECLS) technologies are now more frequently used at centres around the world, according to researchers who analysed data from an international registry. Rate of growth in ECLS use is fastest among adults with respiratory failure. The findings are reported in the ASAIO Journal.
See Also: European Perfusionists in ECLS/ECMO: Roles & Responsibilities
Extracorporeal life support refers to the use of extracorporeal membrane oxygenation (ECMO) and other techniques to provide blood circulation and oxygenation for certain groups of critically ill patients. Like cardiopulmonary bypass during surgery, ECLS takes over the work of the heart and lung for a period of days or weeks – rather than just a few hours.
Dr. Ravi Thiagarajan and colleagues reviewed data on ECLS submitted to the Extracorporeal Life Support Organization (ELSO) registry. "The ELSO registry has collected important information on ECLS use from centres worldwide and has helped us understand ECLS utilisation and outcomes," the authors write.
As of July 2016, the ELSO registry included information on 78,397 infants, children, and adults receiving ELCS since 1989. In 2015, the last year of full data collection, ECLS was used in 7,901 patients at 310 centres worldwide. The report shows that ECLS is now being used more often in adults than in newborns with respiratory failure.
Overall, 70 percent of patients were successfully weaned off ECLS, while 58 percent survived to be discharged from the hospital. When ECLS was used for respiratory failure, the rate of survival to discharge was 74 percent for newborns (under 30 days) and 58 percent for older children and adults.
Data analysis also revealed the following trends in ECLS use:
- Newborns with respiratory failure remain the largest group of ECLS patients.
- Adults with respiratory failure are the fastest-growing group of ECLS patients. This trend may reflect the impact of the H1N1 influenza ("swine flu") epidemic, as well as a 2009 study (the CESAR trial) showing that ECMO improves survival in adults with severe respiratory failure.
- ECLS is also used in patients with various causes of cardiac failure: overall rates of survival to hospital discharge were 42 percent for newborns, 51 percent for older children, and 41 percent for adults.
- Use of ECLS is also growing among patients who don't respond to cardiopulmonary resuscitation.
Although ECLS is potentially lifesaving, the patients who need it are severely ill, and remain at high risk of complications and death. As Dr. Thiagarajan and co-authors point out: “Adverse events during the course of ECLS are common, and underscore the need for skilled ECLS management and appropriately trained ECLS personnel and teams.”
Source: Wolters Kluwer Health
Image Credit: Wikimedia Commons
Published on : Sat, 24 Dec 2016
Print as PDF
Features The SynoVent E5 is the ventilator you need with the interface you want. It does not only include advanced ventilator functionality for patients ranging from infant to adult, but also a modern, easy-to-use interface. The display can be configured...
The HAMILTON-C6 represents a new Generation of high-end ventilators. The combination of modularity, ease of use, mobility, and advanced features allows you to individualize your patient's ventilation therapy: - State-of-the-art ventilation modes for adult,...
XENIOS AG is a medical device company with the three brands, novalung, i-cor and medos, that run on a single XENIOS platform. This platform enables next-generation therapies for lung and heart failure. No other company except XENIOS AG is offering lung...
Features The SynoVent E3 does not only include advanced ventilator functionality but also a modern, easy to use interface. The display can be configured to suit each clinician’s taste and needs, and gives quick and easy control over ventilator parameters...
The fully featured ICU ventilator, HAMILTON-MR1, guarantees uncompromised continuous ventilation care from the ICU to the MRI scanner and back. Its reliability and high performance, with advanced lung-protective strategies and patient-adaptive modes,...